Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: DasKloster 1000; DasKloster 1000-01; DasKloster 1000-02; DasKloster 1000-03; DasKloster 1000-04; DK 1000; Vasoactive intestinal peptide

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator mondoBIOTECH
  • Developer Lung Rx; mondoBIOTECH; RELIEF THERAPEUTICS Holding
  • Class Gastrointestinal hormones; Neuropeptides; Peptide hormones
  • Mechanism of Action Vasoactive intestinal peptide receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pulmonary hypertension; Adult respiratory distress syndrome; Pulmonary sarcoidosis; Acute lung injury; Idiopathic pulmonary fibrosis
  • New Molecular Entity Yes
  • Available For Licensing Yes - Acute lung injury; Adult respiratory distress syndrome; Chronic obstructive pulmonary disease; Pulmonary hypertension; Pulmonary sarcoidosis

Highest Development Phases

  • Phase III Pulmonary sarcoidosis
  • Phase II Adult respiratory distress syndrome
  • Discontinued Idiopathic pulmonary fibrosis; Pulmonary arterial hypertension

Most Recent Events

  • 18 Jul 2016 Phase-II clinical trials in Adult respiratory distress syndrome in Switzerland (Parenteral)
  • 18 Jul 2016 Phase-III for Pulmonary sarcoidosis in European Union (Inhalation)
  • 21 Apr 2016 THERAMetrics enter into a binding agreement to combine with Relief Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top